Skip to content

Study · Non-randomized trial · n = 18 · 1987

9 results

Treatment of growth-hormone deficiency with growth-hormone-releasing hormone.

Ross RJ, Rodda C, Tsagarakis S, Davies PS, Grossman A, Rees LH, Preece MA, Savage MO, Besser GM

Lancet (London, England)1 Jan 1987Cited by 38 (Europe PMC)

PMID2879138 (opens in a new tab)DOI10.1016/s0140-6736(87)90699-4 (opens in a new tab)PepBankPUB-02879138
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In prepubertal GH-deficient children, height velocity rose on GHRH(1-29)NH2 treatment in 12 of 18 children.

    In plain wordsIn children with growth hormone deficiency, growth speed rose with GHRH injections in 12 of 18 children, with no control group.

    Peptide
    Sermorelin
    Outcome
    IncreaseHeight velocity
    Study

    n = 18

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In 12 of the children the height velocity rose on GHRH treatment
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.
  2. 02HumanNon-randomized trialEfficacy outcome

    In prepubertal GH-deficient children, 8 of 18 had a worthwhile response, with height velocity up by more than 2 cm/yr in the first 6 months.

    In plain wordsIn children with growth hormone deficiency, 8 of 18 grew clearly faster in the first 6 months of GHRH injections.

    Peptide
    Sermorelin
    Outcome
    IncreaseWorthwhile response (height velocity increase greater than 2 cm/yr)
    Study

    n = 18

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Height velocity increase
    2.7 to 11.2 cm/yr
    8 responders, first 6 months

    Source sentences

    Summary
    and 8 were judged to have shown a worthwhile response to therapy in that their height velocities during the first 6 months of treatment increased by greater than 2 cm/yr (range 2.7-11.2 cm/yr).
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.
  3. 03HumanNon-randomized trialOther

    A pretreatment peak serum GH above 30 mU/l during an intravenous GHRH test predicted a good growth response, but a lower peak did not preclude one.

    In plain wordsA higher growth hormone peak in a GHRH test before treatment predicted a good growth response, though a lower peak did not rule one out.

    Peptide
    Sermorelin
    Outcome
    Not applicablePretreatment peak GH response as predictor of growth response
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A pretreatment peak serum GH response of above 30 mU/l during an intravenous GHRH test was predictive of a good growth response to GHRH but a lower peak did not preclude a growth response.
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.
  4. 04HumanNon-randomized trialEfficacy outcome

    In GH-deficient children, there was no consistent evidence that GHRH therapy primed or desensitised the GH responses to GHRH.

    In plain wordsIn children with growth hormone deficiency, GHRH treatment did not consistently raise or lower the later growth hormone response to GHRH.

    Peptide
    Sermorelin
    Outcome
    No significant changePriming or desensitisation of GH response
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There was no consistent evidence of a priming or desensitisation effect of therapy on the GH responses to GHRH.
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.
  5. 05HumanNon-randomized trialSafety outcome

    Anti-GHRH antibodies developed in 14 GH-deficient children treated with GHRH(1-29)NH2.

    In plain wordsIn children with growth hormone deficiency, 14 developed antibodies against GHRH during treatment.

    Peptide
    Sermorelin
    Outcome
    IncreaseAnti-GHRH antibody development
    Study

    n = 18

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Although anti-GHRH antibodies developed in 14 patients
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.
  6. 06HumanNon-randomized trialSafety outcome

    Four of 14 patients who had previously received hGH showed growth deceleration with GHRH(1-29)NH2, for unknown reasons.

    In plain wordsIn 4 of 14 children who had earlier taken growth hormone, growth slowed on GHRH injections, for unknown reasons.

    Peptide
    Sermorelin
    Outcome
    DecreaseGrowth deceleration on GHRH
    Study

    n = 14

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    4 of these patients showed growth deceleration with GHRH, for unknown reasons.
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.
  7. 07HumanNon-randomized trialOther

    In 14 patients who had previously received hGH, height velocity on hGH correlated with that on GHRH(1-29)NH2.

    In plain wordsIn 14 children who had earlier taken growth hormone, growth speed on growth hormone matched growth speed on GHRH.

    Peptide
    Sermorelin
    Outcome
    Not applicableCorrelation of height velocity on hGH and on GHRH
    Study

    n = 14

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the 14 patients who had previously received human GH (hGH) height velocity on hGH correlated with that on GHRH.
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.
  8. 08HumanNon-randomized trialSafety outcome

    In GH-deficient children, anti-GHRH antibodies did not seem to have adverse effects on growth or GH responses to GHRH.

    In plain wordsIn children with growth hormone deficiency, the antibodies against GHRH did not seem to harm growth or the growth hormone response.

    Peptide
    Sermorelin
    Outcome
    No significant changeEffect of anti-GHRH antibodies on growth and GH response
    Study

    n = 14

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    these did not seem to have adverse effects on either growth or the GH responses to GHRH.
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.
  9. 09HumanNon-randomized trialEfficacy outcome

    In the 8 responding children treated for 6 to 18 months, the increase in height velocity was maintained.

    In plain wordsIn the 8 children who responded, faster growth continued for 6 to 18 months of GHRH treatment.

    Peptide
    Sermorelin
    Outcome
    IncreaseMaintenance of height velocity increase
    Study

    n = 8

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 6 to 18 monthsAs given in this study (human).

    Source sentences

    Summary
    These 8 children have now been treated for 6 to 18 months and their increase in height velocity has been maintained.
    1 context sentence
    Summary · context
    18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.